ClinicalTrials.gg
RecruitingNCT07689682O-MEG-A-MINDUpdated Oct 22, 2026

OPM- MEG in Non-immune And iMmune-medIated Neurological Disease

An interventional study of OPM- Magnetoencephalography in Autoimmune Encephalitis (AE), Acute Disseminated Encephalomyelitis and Multiple Sclerosis, sponsored by Aston University. Recruiting at 2 sites in United Kingdom. Open to participants aged 2 Years to 16 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-22.

Primary conditionMultiple SclerosisRegistry: Autoimmune Diseases of the Nervous SystemReclassifiedWhy we changed it
Registry
Autoimmune Diseases of the Nervous System — the first condition term the registry derived for this study.
ClinicalTrials.gg
Multiple Sclerosis
Why
  1. The study's listed conditions name Multiple Sclerosis, a narrower term within Autoimmune Diseases of the Nervous System.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Aston University · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Oct 22, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Not applicable
Ages
2 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 252 studies in Multiple Sclerosis with a site in United Kingdom — 28 open to participants now, 46 under way, 11 of them phase 3. Multiple Sclerosis · United Kingdom.

Planned enrollment
111th of 195
90 · median 136
Started
2026
with 4 others
No phase
43 of 252
9 open now
Primary completion
2034-09
later than 45 of 45 live
Registered
250th of 252
by date

Among the 252 studies in Multiple Sclerosis with a site in United Kingdom, this one is the 111th largest by planned enrollment of the 195 interventional ones that give a count, is one of 5 that started in 2026, is one of 43 with no phase, reaches primary completion later than 45 of the 45 other live ones, and was the 250th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

28 of the 252 studies in Multiple Sclerosis with a site in United Kingdom are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 2 Years to 16 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 252 studies in Multiple Sclerosis with a site in United Kingdom, or all of them as a file.
02

Study summary

Over the past 20 years, doctors have gotten much better at spotting and treating brain conditions caused by the immune system attacking the body. These include illnesses like autoimmune encephalitis, ADEM, and multiple sclerosis. But even with better treatments, many patients-especially children-still struggle with long-term problems. Standard brain scans and tests often miss important issues like memory problems, emotional difficulties, trouble sleeping, and challenges with social behaviour. Early research using a special brain imaging technique (called MEG) has shown changes in brain networks that seem to be linked to poor memory. This study will use a new, advanced version of MEG that works even with very young children (as young as 2 years old). The goal is to better understand how these brain conditions affect children, compare them with other types of brain illness, and eventually use this technology to help predict outcomes and discover new ways to track brain health.

Read the detailed description

This study is an 8-year cross-sectional and observational cohort study involving the use of OPM-MEG, MEG, MRI and neuropsychology testing based at the Aston Institute of Health and Neurodevelopment, Birmingham, UK. Children and young people with immune and non-immune mediated neurological disease aged 2-15 years will be recruited locally (Birmingham Children's Hospital) and from London and Manchester.

The longitudinal cohorts (n=25 in each, total n=50) will be those with immune- and non-immune mediated neurological disease within 9 months of diagnosis. They will be invited for 3 study visits (Study Visits 1, 2 and 3).

The cross-sectional cohort (n=25) will be those with immune-mediated neurological disease at least 18 months after diagnosis. They will be invited to for one study visit (Study Visit 1).

The study visits:

At Study Visit 1 (Baseline), participants will undergo OPM-MEG, MEG and MRI as well as neuropsychology testing and questionnaire completion. Total time taken is 5 hours. This visit can be split into 2 visits within a 2 week window.

At Study Visit 2 (2 years)and 3 (5 years) participants will undergo OPM-MEG, MEG and MRI and questionnaire completion. Total time taken is 3 hours.

Participants travelling from outside the West Midlands will be offered overnight accommodation for Study Visits.

The participants are welcome to have as many breaks as is necessary during each/any Study Visit. It is expected that breaks will last between 15 minutes to one hour. Refreshments will be available for the participants on the day and will ask in advance of the visit in case of any allergies. Aston University, where the IHN is based, has food outlets Tesco, Greggs and Costa Coffee available too. Another adult, aside from the research team, can be present during the research recordings.

03

Conditions studied

  • Autoimmune Encephalitis (AE)
  • Acute Disseminated Encephalomyelitis
  • Multiple Sclerosis

Browse trials for

Keywords

  • neuroimaging
  • autoimmune encephalitis
  • ADEM
  • magnetoencephalography
  • OPM-MEG
04

In context

Multiple Sclerosis Reclassified

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

This study's planned enrollment of 90 is above the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.

Browse Multiple Sclerosis studies →

Lead sponsor

Aston University is the lead sponsor of 27 studies on the registry; 8 are open to participants now.

Compared within Multiple Sclerosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Autoimmune Diseases of the Nervous System. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
2 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals (age range 2 yrs to 16 years) who have received a diagnosis of immune-mediated neurological disease e.g. encephalitis1, acute disseminated encephalomyelitis, multiple sclerosis. 2
  • Individuals who have received a diagnosis of a non-immune mediated neurological disease (age range 2 yrs to 15 years 11 months) e.g. stroke.
  • Patients who can give / assent and have a person with parental responsibility capable of giving informed consent on their behalf if aged \<16 years.

Exclusion criteria

Exclusion Criteria:

  • There is metal in the body or any other that precludes MRI scanning at IHN, or child usually requires sedation for clinical MRI scans.
  • Participant dissents.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Cross-sectional - participants who have had a neuroimmunological condition over 18 months ago

    Longitudinal - participants who are within 9 months of disease

    Device: OPM- Magnetoencephalography

Interventions

  • DeviceOPM- Magnetoencephalography

    To assess the changes in brain network function that occur in relation to immune and non-immune mediated brain disease, participants will undergo OPM-MEG recording. This will be conducted at all study visits. To assess the behavioural and functional changes following disease from the patient and caregiver perspective questionnaires will be completed on paper-based forms. These are all established outcomes measures used in our and others' previous studies in immune and non-immune mediated disease in children. The cryogenic MEG recording will also assess changes in brain dysfunction and will be directly comparable to the advanced OPM-MEG data. To assess the effect of disease on brain structures, participants will undergo MRI scanning at the IHN. To assess functional outcomes of immune and non-immune mediated disease, participants will undergo neuropsychology assessments.

    Also known as: MRI, neuropsychology assessment

07

What researchers measure

Primary outcomes

  1. Detection of group differences over time in imaging metrics using OPM-MEG.

    Change from Baseline in OPM-MEG Resting-State Delta-Band (1-4 Hz) Local Efficiency Local efficiency of resting-state brain networks derived from OPM-MEG recordings, computed from amplitude envelope correlation connectivity matrices (Desikan-Killiany atlas parcellation) using the Brain Connectivity Toolbox, compared between participants with immune-mediated and non-immune-mediated neurological disease across proportional connectivity thresholds (10-30%).

    Time frame: Baseline (Study Visit 1), 2 years (Study Visit 2), 5 years (Study Visit 3)

Secondary outcomes

  1. Change from Baseline in Whole-Brain Cortical Thickness

    Mean cortical thickness across the whole brain, measured from T1-weighted MRI using FreeSurfer surface-based analysis, compared between disease groups.

    Time frame: Baseline, 2 years, 5 years

  2. Correlation Between Resting-State Network Graph Measures and Wechsler Working Memory Index Score

    Association between OPM-MEG/MEG-derived delta and theta local efficiency, global efficiency, and modularity values (particularly theta modularity) and Working Memory Index composite scores from the Wechsler Intelligence Scale for Children - Fifth Edition and the Wechsler Preschool and Primary Scale of Intelligence - Fourth Edition (WISC-V/WPPSI-4), analyzed by multiple regression controlling for sex. On the WISC-V and WPPSI-IV, the theoretical minimum Full Scale IQ score is 40 and the maximum score is 160, with higher scores indicating better cognitive outcomes and stronger academic potential.

    Time frame: Baseline, 2 years, 5 years

  3. Diagnostic/Predictive Performance of Imaging Metrics for Clinical Outcome Group (mRS-Defined)

    Sensitivity/specificity or area-under-curve of OPM-MEG, MEG, and MRI-derived metrics (local efficiency, modularity, cortical thickness) for classifying participants by modified Rankin Scale outcome category at follow-up.

    Time frame: 2 years, 5 years

08

Study locations

2 of 2 sites recruiting
09

References and documents

Publications

  • Nosadini M, Eyre M, Molteni E, Thomas T, Irani SR, Dalmau J, Dale RC, Lim M; International NMDAR Antibody Encephalitis Consensus Group; Anlar B, Armangue T, Benseler S, Cellucci T, Deiva K, Gallentine W, Gombolay G, Gorman MP, Hacohen Y, Jiang Y, Lim BC, Muscal E, Ndondo A, Neuteboom R, Rostasy K, Sakuma H, Sartori S, Sharma S, Tenembaum SN, Van Mater HA, Wells E, Wickstrom R, Yeshokumar AK. Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis: A Meta-analysis. JAMA Neurol. 2021 Nov 1;78(11):1333-1344. doi: 10.1001/jamaneurol.2021.3188. PubMed 34542573 ↗
  • Billaud CHA, Wood AG, Griffiths-King D, Kessler K, Wassmer E, Foley E, Wright SK. Examining cognition and brain networks using magnetoencephalography in paediatric autoimmune encephalitis and acute disseminated encephalomyelitis: a preliminary study. Brain Commun. 2024 Aug 8;6(4):fcae248. doi: 10.1093/braincomms/fcae248. eCollection 2024. PubMed 39130516 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this cohort may be highly valuable to future research efforts. Thus, we will ask participants to provide written informed consent to make their anonymised data freely available for reanalysis by the team in future studies, and to researchers outside of the study team for use in ethically approved projects. Specifically, neuroimaging (MRI), questionnaire, neuropsychology (summary scores) and demographic data that are suitable for sharing will be made available, using open-access data repositories platforms such as OSF (osf.org) or other suitable platforms which meet current best practice within the field, in relation to local and national regulations (i.e. GDPR). Open-access sharing of data will only happen once the linking document (linking study ID to personal identifiable data i.e. name) is destroyed (3 years after study end), to ensure that shared data is truly anonymous, not pseudo-anonymised

Supporting information: Study protocol

Time frame: 3 years after study end after linking document destroyed September 2037 to September 2047

Access criteria: Only the PI and study team

Data sharing details ↗ · www.aston.ac.uk

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Sep 2034, 100 months after the start.

Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 100 months is above that.

Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2026
First posted
Jul 8, 2026
StartActual
May 15, 2026
Primary completionEst.
Sep 15, 2034
CompletionEst.
Sep 15, 2034
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Oct 22, 2026
Sites
1 site added. Aston University is now Recruiting
Show site
  • Birmingham Children's Hospital · Birmingham, United Kingdom
Oct 22, 2026
Contact
Study contact now listed: added o•••@aston.ac.uk · •••3076. See the current contact
Oct 22, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Aston University · Birmingham, United KingdomContact added m•••@aston.ac.uk · •••5069
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Active, not recruiting→Recruiting
    1 site added. Aston University is now Recruiting
    Show site
    • Birmingham Children's Hospital · Birmingham, United Kingdom
    Contact Study contact now listed: added o•••@aston.ac.uk · •••3076. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Aston University · Birmingham, United KingdomContact added m•••@aston.ac.uk · •••5069
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07689682
Lead sponsor
Aston University
Collaborators
Birmingham Children's Hospital, United Kingdom
Responsible party
Sponsor
First posted
Jul 8, 2026
Start date
May 15, 2026
Primary completion
Sep 15, 2034 (estimated)
Completion
Sep 15, 2034 (estimated)
Last update
Oct 22, 2026

Study contacts

Sukhvir Wright, MBBS, DPhil
Contact
omegamind@aston.ac.uk
+44 121 204 3076
Sukhvir Wright
principal investigator · Aston University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion